Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
Vir Biotechnology (VIR) filed an 8-K to disclose a material R&D milestone. On 24 Jul 2025 the company dosed the first patient in a Phase 1 trial of VIR-5525, an investigational dual-masked T-cell engager that targets EGFR-expressing tumors. Management reported the event under Item 8.01 and attached the related press release as Exhibit 99.1. No financial results, guidance or partnering details were included.
The dosing signals the formal clinical start of VIR-5525 and expands VIR’s oncology pipeline beyond its infectious-disease franchise. While the filing does not quantify trial size, endpoints or timelines, Phase 1 initiation is typically a prerequisite for value-creating data read-outs and potential future partnerships. Investors should note, however, that first-in-human studies are high-risk and non-revenue-generating at this stage.